Hepatitis C Guidance 2023 Update: American Association for the Study of Liver Diseases– Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection

Aronsohn, Andrew; Bhattacharya, Debika; Re, Vincent Lo; Price, Jennifer; Feld, Jordan J.; Gordon, Stuart C.; Heller, Theo; Jhaveri, Ravi; Jonas, Maureen M.; Kiser, Jennifer J.; Linas, Benjamin P.; Morgan, Timothy R.; Reddy, K. Rajender; Reynolds, Andrew; Scott, John D.; Searson, Gloria; Spradling, Philip R.; Terrault, Norah A.; Verna, Elizabeth C.; Wong, John B.; Workowski, Kimberly A.; Wyles, David L.

doi:10.1093/cid/ciad319

Cited by 59 publications

(53 citation statements)

References 144 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In Western countries, 8-week GLE/PIB therapy is implemented even in patients with cirrhosis, and a high SVR rate is observed. [31][32][33] This result also supports our findings. Therefore, even if liver fibrosis status is underestimated in patients with cirrhosis (as defined by FIB-4 >3.25) and shorter treatment periods (8 weeks) are chosen, high efficacy could be expected.…”

Section: Discussionsupporting

confidence: 91%

Effect of treatment periods on efficacy of glecaprevir and pibrentasvir in chronic hepatitis C: A nationwide, prospective, multicenter study

Morita,

Tamaki,

Kobashi

et al. 2024

JGH Open

View full text Add to dashboard Cite

Background and aimIn patients with chronic hepatitis C, 8 weeks of glecaprevir and pibrentasvir (GLE/PIB) treatment for chronic hepatitis (non‐cirrhosis) and 12 weeks for cirrhosis have been approved in Japan. However, whether 8 weeks of treatment for cirrhosis may reduce treatment efficacy has not been adequately investigated.MethodsThis prospective, nationwide, multicenter cohort study enrolled 1275 patients with chronic hepatitis C who received GLE/PIB therapy. The effect of liver fibrosis and treatment periods on the efficiency of GLE/PIB therapy was investigated. The primary endpoint was the sustained virological response (SVR) rate in patients with chronic hepatitis (non‐cirrhosis) and cirrhosis. The association between treatment periods and liver fibrosis on the SVR after 12 weeks of treatment rate was investigated.ResultsThe SVR rates in patients with chronic hepatitis with 8 weeks of treatment, chronic hepatitis with 12 weeks of treatment, cirrhosis with 8 weeks of treatment, and cirrhosis with 12 weeks of treatment were 98.9% (800/809), 100% (87/87), 100% (166/166), and 99.1% (211/213), respectively, and were was not different among these groups (P = 0.4).ConclusionGLE/PIB therapy for chronic hepatitis C had high efficacy regardless of liver fibrosis status and treatment periods. Periods of GLE/PIB therapy could be chosen with available modalities, and high SVR rates could be achieved regardless of the decision.

show abstract

Section: Discussionsupporting

confidence: 91%

Effect of treatment periods on efficacy of glecaprevir and pibrentasvir in chronic hepatitis C: A nationwide, prospective, multicenter study

Morita,

Tamaki,

Kobashi

et al. 2024

JGH Open

View full text Add to dashboard Cite

show abstract

“…Several direct-acting antiviral regimens are available for treatment of HCV infection, with the goal of eradicating HCV infection in most individuals. 36 One of the primary advantages of universal HCV screening during pregnancy is identification of individuals with HCV infection so that treatment can be offered while patients are highly engaged in the health care system, as often occurs during the perinatal period. However, the lack of safety data on breastfeeding while taking direct-acting antivirals may contribute to lower rates of breastfeeding initiation.…”

Section: Discussionmentioning

confidence: 99%

Breastfeeding Initiation in People With Hepatitis C Virus Infection in the United States

Blauvelt,

Turcios,

Wen

et al. 2024

Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

OBJECTIVE: To evaluate breastfeeding initiation rates among people living with and without hepatitis C virus (HCV) infection during pregnancy and to identify characteristics associated with breastfeeding initiation. METHODS: We conducted a cross-sectional analysis of individuals who had a live birth in the United States from 2016 to 2021 using the National Center for Health Statistics birth certificate data. We grouped participants by whether they had HCV infection during pregnancy. Using propensity-score matching, we assessed the association between breastfeeding initiation before hospital discharge, defined as neonates receiving any parental breast milk or colostrum, and HCV infection during pregnancy in a logistic regression model. We also assessed factors associated with breastfeeding initiation among those with HCV infection. RESULTS: There were 96,896 reported cases (0.5%) of HCV infection among 19.0 million births that met inclusion criteria during the study period. Using propensity-score matching, we matched 87,761 individuals with HCV infection during pregnancy with 87,761 individuals without HCV infection. People with HCV infection during pregnancy were less likely to initiate breastfeeding compared with those without HCV infection (51.5% vs 64.2%, respectively; odds ratio 0.59, 95% CI, 0.58–0.60, P<.001). Characteristics associated with higher rates of breastfeeding initiation among individuals with HCV infection included a college degree (adjusted odds ratio [aOR] 1.22, 95% CI, 1.21–1.24); self-identified race or ethnicity as Native Hawaiian or Pacific Islander (aOR 1.22, 95% CI, 1.06–1.40), Asian (aOR 1.09, 95% CI, 1.06–1.13), or Hispanic (aOR 1.09, 95% CI, 1.08–1.11); private insurance (aOR 1.07, 95% CI, 1.06–1.08); nulliparity (aOR 1.09, 95% CI, 1.08–1.10), and being married (aOR 1.08, 95% CI, 1.07–1.09). Characteristics associated with not breastfeeding before hospital discharge included receiving no prenatal care (aOR 0.81, 95% CI, 0.79–0.82), smoking during pregnancy (aOR 0.88, 95% CI, 0.88–0.89), and neonatal intensive care unit admission (aOR 0.92, 95% CI, 0.91–0.93). CONCLUSION: Despite leading health organizations’ support for people living with HCV infection to breastfeed, our study demonstrates low breastfeeding initiation rates in this population. Our findings highlight the need for tailored breastfeeding support for people with HCV infection and for understanding the additional effects of human immunodeficiency virus (HIV) co-infection, HCV treatment, and concurrent substance use disorders on breastfeeding initiation.

show abstract

“…Current pangenotypic regimens to treat naı̈ve infected adults without cirrhosis or with compensated cirrhosis consist of (a) glecaprevir ( 74 )/pibrentasvir ( 3 ) (gt1–6); (b) sofosbuvir ( 5 )/velpatasvir ( 4 ) (gt1–6); (c) ledipasvir ( 2 )/sofosbuvir ( 5 ) (gt1, 4–6); (d) elbasvir ( 2 )/grazoprevir ( 52 ) (gt1b and gt4); (e) sofosbuvir ( 5 )/velpatasvir ( 4 )/voxilaprevir ( 71 ) (gt1–6)…”

Section: Hcv Infection and Current Treatmentmentioning

confidence: 99%

Hepatitis C: The Story of a Long Journey through First, Second, and Third Generation NS3/4A Peptidomimetic Inhibitors. What Did We Learn?

Martino,

Petri,

De Rosa

2024

J. Med. Chem.

View full text Add to dashboard Cite

Hepatitis C viral (HCV) infection is the leading cause of liver failure and still represents a global health burden. Over the past decade, great advancements made HCV curable, and sustained viral remission significantly improved to more than 98%. Historical treatment with pegylated interferon alpha and ribavirin has been displaced by combinations of direct-acting antivirals. These regimens include drugs targeting different stages of the HCV life cycle. However, the emergence of viral resistance remains a big concern. The design of peptidomimetic inhibitors (PIs) able to fit and fill the conserved substrate envelope region within the active site helped avoid contact with the vulnerable sites of the most common resistance-associated substitutions Arg155, Ala156, and Asp168. Herein, we give an overview of HCV NS3 PIs discovered during the past decade, and we deeply discuss the rationale behind the structural optimization efforts essential to achieve pangenotypic activity.

show abstract

Hepatitis C Guidance 2023 Update: American Association for the Study of Liver Diseases– Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection

Cited by 59 publications

References 144 publications

Effect of treatment periods on efficacy of glecaprevir and pibrentasvir in chronic hepatitis C: A nationwide, prospective, multicenter study

Effect of treatment periods on efficacy of glecaprevir and pibrentasvir in chronic hepatitis C: A nationwide, prospective, multicenter study

Breastfeeding Initiation in People With Hepatitis C Virus Infection in the United States

Hepatitis C: The Story of a Long Journey through First, Second, and Third Generation NS3/4A Peptidomimetic Inhibitors. What Did We Learn?

Contact Info

Product

Resources

About